QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module IX: Signal Detection, Validation and Confirmation

Test your understanding of the concepts covered by GVP Module IX: Signal Detection, Validation and Confirmation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A disproportionality analysis shows that a product-event combination is reported more often than expected. What is the most appropriate interpretation?

The result proves that the product caused the event The result demonstrates an increased incidence in treated patients The result identifies a pattern requiring clinical and scientific context The result can be disregarded because spontaneous reports lack complete exposure data

Question 2 of 10 Why should signal management and aggregate reporting processes be connected?

Because a PSUR automatically confirms every validated signal Because each process is legally identical and cannot operate separately Because information may flow in both directions and disconnected teams can produce missed information or inconsistent conclusions Because aggregate reports replace individual case review

Question 3 of 10 What is the appropriate interpretation of improvement after treatment withdrawal in an individual case?

It proves causality in every circumstance It can support a causal hypothesis but must be interpreted against spontaneous recovery and other interventions It has no relevance to signal assessment It is stronger evidence than recurrence after re-exposure in all circumstances

Question 4 of 10 A medicine's use doubles and the number of spontaneous reports of an event also doubles. What conclusion is most justified from this information alone?

The incidence of the event has doubled The medicine has become more toxic The increase in reports may reflect increased exposure rather than increased underlying risk The signal should automatically be confirmed

Question 5 of 10 Which factor could create an apparent disproportionality that is not caused by the medicinal product itself?

Indication-related risk or co-medication The existence of a formal signal owner A documented validation rationale A consistent clinical phenotype across independent datasets

Question 6 of 10 Which statement best describes the relationship between a regulatory authority's action and the MAH's internal signal-management process?

Regulatory action eliminates the need for internal reassessment The MAH should determine whether the action introduces new evidence or requires changes to the signal status, safety profile or risk-management measures Internal records should remain unchanged because the authority owns the signal Regulatory intelligence is separate from pharmacovigilance signal governance

Question 7 of 10 A company has a strong statistical alert but inconsistent diagnoses, substantial co-medication and no coherent temporal pattern. What is the most appropriate conclusion?

The alert confirms the safety risk because the statistical elevation is marked The alert should be ignored because clinical data are imperfect The alert requires documented clinical assessment and evaluation of alternatives before a validation or confirmation decision The event should be added immediately to product information

Question 8 of 10 Why should signal management examine new aspects of known risks?

Known risks are excluded from all further monitoring A known event may show a materially different severity, latency, population, dose relationship or interaction pattern Only new event terms can have regulatory significance New aspects of known risks are relevant only to clinical trials

Question 9 of 10 Which example best illustrates qualitative signal detection?

An automated algorithm flags a product-event combination above a statistical threshold A clinician recognises a distinctive clinical pattern in a well-documented case series A database calculates the number of reports per reporting year A team assigns a priority category after a signal has been validated

Question 10 of 10 What is the correct relationship between validation and prioritisation?

Prioritisation determines whether an observation qualifies for validation Validation establishes whether further investigation is justified; prioritisation then determines urgency and resources Prioritisation replaces clinical review during validation Both are identical decisions and should use one combined threshold

GVP Module IX: Signal Detection, Validation and Confirmation

Cookie Settings